Sector
PharmaceuticalsOpen
₹474.9Prev. Close
₹475.05Turnover(Lac.)
₹6,656.27Day's High
₹479Day's Low
₹45052 Week's High
₹72152 Week's Low
₹389.35Book Value
₹137.55Face Value
₹1Mkt Cap (₹ Cr.)
10,976.32P/E
35.77EPS
13.3Divi. Yield
0.3215 May 2024
12:00 AM
BookCloser
15 May 2024
12:00 AM
AGM
Announcement Date: 15 May, 2024
25 Mar 2025
12:00 AM
Board Meeting
Agenda : Audited Result
15 May 2024
12:00 AM
Dividend
Dividend Amount: 1.5
Record Date: 30 Jul, 2024
The pharma company caters to various international markets, reinforcing its position as a key player in the pharmaceutical industry.
Granules India, maintaining that it fully intends to respond in the time period allowed, as well as requesting a meeting with the FDA to show progress made in compliance, has taken care to make this clear as well.
The inspection covered Active Pharmaceutical Ingredients (APIs) and Finished Dosages (FDs) for oncology and non-oncology segments, underscoring the plant’s adherence to high manufacturing standards.
Bupropion hydrochloride is widely prescribed for treating major depressive disorder (MDD) and preventing seasonal affective disorder (SAD).
The USFDA has also noted a repeat observation from the company's January 2023 inspection.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 24.24 | 24.2 | 24.8 | 24.77 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 3,086.71 | 2,675.26 | 2,505.86 | 2,137.85 |
Net Worth | 3,110.95 | 2,699.46 | 2,530.66 | 2,162.62 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 3,238.43 | 3,134.98 | 2,309.92 | 1,646.64 |
yoy growth (%) | 3.29 | 35.71 | 40.28 | 22.02 |
Raw materials | -1,757.74 | -1,509.64 | -1,221.98 | -903.09 |
As % of sales | 54.27 | 48.15 | 52.9 | 54.84 |
Employee costs | -282.79 | -318.25 | -192.51 | -147.92 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 519.64 | 732.87 | 391.9 | 208.45 |
Depreciation | -126.16 | -118.45 | -101.82 | -75.91 |
Tax paid | -133.13 | -180.08 | -108.95 | -69.29 |
Working capital | 350.84 | 159.58 | 230.57 | 276.19 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 3.29 | 35.71 | 40.28 | 22.02 |
Op profit growth | -25.16 | 74.31 | 68.34 | -0.76 |
EBIT growth | -29.16 | 80.68 | 73.48 | 1 |
Net profit growth | -30.07 | 24.48 | 219.1 | -2.56 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 4,490.16 | 4,511.92 | 3,764.92 | 3,237.54 | 2,598.65 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 4,490.16 | 4,511.92 | 3,764.92 | 3,237.54 | 2,598.65 |
Other Operating Income | 16.21 | 0 | 0 | 0 | 0 |
Other Income | 4.4 | 13.78 | 17.61 | 26.88 | 89.79 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,787.4 | 137.43 | 4,32,960 | 1,181.05 | 0.75 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,012.5 | 79.59 | 1,65,003.32 | 594 | 0.48 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,525.9 | 26.92 | 1,25,285.64 | 1,438.15 | 0.84 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,238.9 | 61.67 | 1,12,502.67 | 485 | 0.84 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,557.5 | 55.53 | 1,07,385.94 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
C Krishna Prasad
Executive Director
Harsha Chigurupati
Executive Director
Uma Devi Chigurupati
Non-Exec & Non-Independent Dir
K B Sankara Rao
Company Sec. & Compli. Officer
Chaitanya Tummala
Non-Exec. & Independent Dir.
Arun Sawhney
Independent Director
Saumen Chakraborty
Independent Director
Sucharita Rao Palepu
Joint Managing Director & CEO
KVS Ram Rao
Independent Director
Kapil Mehan
Independent Director
Rajiv Kakodkar
Executive Director
Priyanka
Independent Director
S Ravi
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Granules India Ltd
Summary
Granules India Limited is a large-scale vertically integrated company founded in March 18th, 1991 manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Finished Dosage (FD). With a strong presence across all three vertical, the company has created a leadership position in the off-patent drugs segment along with ensuring a strong presence in first line of defense products such as Paracetamol, Ibuprofen, Metformin and Guaifenesin. The company has a global presence across over 80 countries servicing over 300 customers. Granules India is the preferred supplier for some of the worlds leading pharma branded and generics companies. The company has one of largest PFI and single site FD facilities in the world. It is also home to one of the Worlds largest Paracetamol API facilities.Granules India has 8 manufacturing facilities, out of which six are located in India and two in the US. It also has two operational manufacturing units located in India and China through its joint venture entities. The company has 250 customers present across 60 countries around the globe. The companys research center at Pragathi Nagar, Hyderabad, spread across an area of 15,000 square feet, epitomizes the companys focus on research and development. It mainly focuses on full-scale generic API development.Incorporated as a private limited company in 1991, Granules India (GIL) was converted into a public limited company in Feb.93. It commenced its operations i
Read More
What is the Granules India Ltd share price today?
The Granules India Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹452.55 today.
What is the Market Cap of Granules India Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Granules India Ltd is ₹10976.32 Cr. as of 25 Apr ‘25
What is the PE and PB ratio of Granules India Ltd?
The PE and PB ratios of Granules India Ltd is 35.77 and 3.59 as of 25 Apr ‘25
What is the 52 Week High and Low of Granules India Ltd?
The 52-week high/low is the highest and lowest price at which a Granules India Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Granules India Ltd is ₹389.35 and ₹721 as of 25 Apr ‘25
What is the CAGR of Granules India Ltd?
Granules India Ltd's CAGR for 5 Years at 23.20%, 3 Years at 18.35%, 1 Year at 13.62%, 6 Month at -14.71%, 3 Month at -18.38% and 1 Month at -7.12%.
What is the shareholding pattern of Granules India Ltd?
The shareholding pattern of Granules India Ltd is as follows:
Promoters - 38.84 %
Institutions - 37.59 %
Public - 23.57 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
